GainersToday.com
GainersToday.com, Tracking Stock Market Picks
Enter Symbol:
 
Gilead Sciences, Inc. (GILD) [hlAlert]

Rating:
Outperform
GILD
up 330.06 %

Gilead Sciences, Inc. (GILD) rated Outperform with price target $124 by Oppenheimer

Posted on: Tuesday,  Oct 20, 2015  11:25 AM ET by Oppenheimer

Oppenheimer rated Outperform Gilead Sciences, Inc. (NASDAQ: GILD) on 10/20/2015. Previously Oppenheimer rated Outperform Gilead Sciences, Inc. (NASDAQ: GILD) on 04/17/2008.,
when the stock price was $25.11. Since then, Gilead Sciences, Inc. has gained 330.07% as of 10/28/2015's recent price of $107.99.
If you would have followed the previous Oppenheimer's recommendation on GILD, you would have gained 330.06% of your investment in 2750 days.

Gilead Sciences, Inc. (Gilead) is a biopharmaceutical company that discovers, develops, and commercializes therapeutics in areas of unmet medical need. The Company has United States and international commercial sales operations, with marketing subsidiaries in Australia, Austria, Canada, France, Germany, Greece, Ireland, Italy, New Zealand, Portugal, Spain, Switzerland, Turkey, United Kingdom, and United States. Its commercial team promotes Truvada, Viread, Emtriva, Hepsera, AmBisome, Letairis, and Flolan through direct field contact with physicians, hospitals, clinics, and other healthcare providers. Gilead?s corporate partner, Astellas Pharma, Inc. (Astellas), promotes and sells AmBisome in the United States, Canada, Europe, Australia, and New Zealand. In May 2008, the Company acquired Navitas Assets, LLC?s. In April 2009, the Company announced the completion of its acquisition of CV Therapeutics, Inc.

OppenheimerFunds, Inc. has been helping investors achieve their financial goals since 1960. We are one of the nation's largest and most respected asset management companies. At OppenheimerFunds, we believe that in order for you to reach your financial goals, your investments must perform. That is why investment excellence—over the long term and across the range of our products—is our highest priority. OppenheimerFunds and its controlled affiliates offer a broad range of products and services to individuals, corporations and institutions, including mutual funds, separately managed accounts, investment management for institutions, hedge fund products, qualified retirement plans and subadvisory investment-management services.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
10/20/2015 11:25 AM Buy
None
103.00 124.00
as of 8/27/2015
1 Week down  -5.63 %
1 Month down  -11.63 %
3 Months down  -0.68 %
1 YTD up  43.79 %
Previous Recommendations
Date/Time (ET)SymbolRatingTermPrice (*)Target
5/3/2013 8:25 AM Buy
None
55.87 61.00
4/17/2013 8:25 AM Buy
None
51.56 59.00
3/14/2013 8:25 AM Buy
None
45.83 50.00
7/21/2010 8:25 AM Buy
None
16.25 23.00
4/17/2008 10:25 AM Buy
None
25.11 29.00

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy